Select therapeutic use:

Colorectal and other GI cancers:

Indications for PHOTOFRIN:

Palliation of patients with completely obstructing esophageal cancer or partially obstructing esophageal cancer who cannot be satisfactorily treated with Nd:YAG laser therapy. Ablation of high-grade dysplasia in Barrett's esophagus patients who do not undergo esophagectomy.

Adult:

See full labeling. Give by slow IV inj over 3–5mins. 2mg/kg then illumination with laser light 40–50hrs following injection. Esophageal cancer: 2nd course may be given at a minimum of 30 days after initial therapy; max 3 courses (separated by ≥30 days). High-grade dysplasia in Barrett's esophagus: 2nd course may be given at a minimum of 90 days after initial therapy; max 3 courses (separated by ≥90 days).

Children:

Not established.

Contraindications:

Porphyria. Existing tracheoesophageal or bronchoesophageal fistula. Tumors eroding into a major blood vessel. Emergency treatment of patients with severe acute respiratory distress caused by an obstructing endobronchial lesion. Esophageal or gastric varices. Esophageal ulcers >1cm in diameter.

Warnings/Precautions:

Avoid direct sunlight or bright indoor light; wear dark sunglasses when outdoors. Increased risk of fatal massive hemoptysis with large, centrally located tumors, cavitating tumors, extensive tumor extrinsic to the bronchus. Caution with endobronchial tumors in locations where treatment-induced inflammation could obstruct airway; monitor for respiratory distress. Severe renal or hepatic impairment: may prolong photosensitivity period. Avoid extravasation. Embryo-fetal toxicity. Advise females of reproductive potential and males (w. female partners) to use effective contraception during and for 5 months after last dose. Pregnancy; exclude status prior to initiation. Nursing mothers: not recommended (during and for 5 months after last dose).

Pharmacologic Class:

Photosensitizing agent.

Interactions:

Increased risk of photosensitivity reactions with other photosensitizing agents (eg, tetracyclines, sulfonamides, phenothiazines, sulfonylurea hypoglycemic agents, thiazide diuretics, griseofulvin, fluoroquinolones); avoid. Separate radiotherapy by 2–4 weeks.

Adverse Reactions:

Photosensitivity reactions (eg, erythema, swelling, itching, burning sensation, feeling hot, blisters), constipation, pain, GI upset, pyrexia, dyspnea, pneumonia; chest pain, ocular sensitivity, hemoptysis (may be fatal), esophageal strictures, thromboembolism.

How Supplied:

Single-use vial—1

Respiratory and thoracic cancers:

Indications for PHOTOFRIN:

Reduction of obstruction and palliation in patients with completely or partially obstructing endobronchial non-small-cell lung cancer (NSCLC). Treatment of microinvasive endobronchial NSCLC in patients for whom surgery and radiotherapy is not indicated.

Adult:

See full labeling. Give by slow IV inj over 3–5mins. 2mg/kg then illumination with laser light 40–50hrs following injection. 2nd course may be given at a minimum of 30 days after initial therapy; max 3 courses (separated by ≥30 days).

Children:

Not established.

Contraindications:

Porphyria. Existing tracheoesophageal or bronchoesophageal fistula. Tumors eroding into a major blood vessel. Emergency treatment of patients with severe acute respiratory distress caused by an obstructing endobronchial lesion. Esophageal or gastric varices. Esophageal ulcers >1cm in diameter.

Warnings/Precautions:

Avoid direct sunlight or bright indoor light; wear dark sunglasses when outdoors. Increased risk of fatal massive hemoptysis with large, centrally located tumors, cavitating tumors, extensive tumor extrinsic to the bronchus. Caution with endobronchial tumors in locations where treatment-induced inflammation could obstruct airway; monitor for respiratory distress. Severe renal or hepatic impairment: may prolong photosensitivity period. Avoid extravasation. Embryo-fetal toxicity. Advise females of reproductive potential and males (w. female partners) to use effective contraception during and for 5 months after last dose. Pregnancy; exclude status prior to initiation. Nursing mothers: not recommended (during and for 5 months after last dose).

Pharmacologic Class:

Photosensitizing agent.

Interactions:

Increased risk of photosensitivity reactions with other photosensitizing agents (eg, tetracyclines, sulfonamides, phenothiazines, sulfonylurea hypoglycemic agents, thiazide diuretics, griseofulvin, fluoroquinolones); avoid. Separate radiotherapy by 2–4 weeks.

Adverse Reactions:

Photosensitivity reactions (eg, erythema, swelling, itching, burning sensation, feeling hot, blisters), constipation, pain, GI upset, pyrexia, dyspnea, pneumonia; chest pain, ocular sensitivity, hemoptysis (may be fatal), esophageal strictures, thromboembolism.

How Supplied:

Single-use vial—1